



# Omics and AI for PROTON

Selection beyond the standard: practice impact and next steps

---




Dr. Fabian Hennings, 18. October 2022

# I. general challenges in PROTONS

---

# I.a anatomical changes

Finite range:




change in anatomy → change in delivery!

Images by: J. Pietsch & Dr. K. Stützer

## I.b variable RBE

### Relative Biological Effectiveness (RBE):



→ Clinical Standard: RBE-photons + 10%

→ variable RBE:  $\Delta RBE \sim x * 10\%$   
(in the plateau region)

→ RBE ~ physical dose, LET, tissue

Animation by: M. Palkowitsch

<sup>1)</sup> Relative biological effectiveness in proton beam therapy – Current knowledge and future challenges, Lühr, 2018


## II. Clinical benefit

---

How to contribute to the  
wellbeing of patients?

## II.a global scale

### Finding the fitting treatment for the individual patient!



### Model based treatment selection:

- Organs at risk ~ Clinical endpoints
- Estimate clinical benefit
- $\Delta$  NTCP -> treatment selection

Langendijk, 2013, Selection of patients for radiotherapy with protons aiming at reduction of side effects: The model-based approach

## II.a global scale

Finding the fitting treatment for the individual patient!

- simulate variable RBE dependencies
- dose for OaR → NTCP models  
**(Dosiomics/Radiomics?)**
- evaluate on level of sideeffects!
- → Decision Support System (AI)







Image: A Monte Carlo based radiation response modelling framework to assess variability of clinical RBE in proton therapy, Eulitz, 2019

## II.b local scale


### Adapting the plan due to the actual anatomy



# III. practical impacts of OAPT

---


## III.a OAPT workflow



Animation: J. Berthold & J. Pietsch


## III.b aspects of AI development

interaction




- Condensing data (5 facts at a time)
- Presenting information
- transparency
- Supporting decisions





technological




- automation
- acceleration
- structured/ consistent
- tasks oriented



### III.c In-vivo verification: PGI






### III.e human factor

Who is responsible  
for What?

Is the treatment in  
tolerance?

Is this new plan  
acceptable?



establish trust

← →

prevent blind faith

AI = Tool

transparent


understood

participated

# IV. next..?

---

# IV next steps



Benjamin H. Kann, Artificial intelligence for clinical oncology, 2021

**Validity:**

**External testing**


**Utility:**

**RCT?!**


**Usability:**

**actual useful?**

## IV next steps



Benjamin H. Kann, Artificial intelligence for clinical oncology, 2021



# AI is a tool

---

Let's shape and design  
what we hope for!

V

Thank you!

Prof. Dr. Steffen Löck  
Martina Palkowitsch  
Alex Zwanenburg-Bezemer  
Sebastian Starke  
Asier Rabasco Meneghetti  
Prof. Dr. Christian Richter  
Kristin Stützer  
Jonathan Berthold  
Julian Pietsch  
Virginia Gambetta  
Stefanie Bertschi  
Saskia Spautz  
Lukas Wolter



HELMHOLTZ ZENTRUM  
DRESDEN ROSSENDORF

Universitätsklinikum Carl Gustav Carus  
DIE DRESDNER.

